日期: 2025 年 12 月 2 日

ANKARA, Turkey, Dec 2, 2025 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, CA (United States) today.SUL-238 was originally discovered by Sulfateq and has since been further developed through a collaborative effort of Sulfateq and GEN as a novel therapeutic in neurodegenerative diseases.This Phase 1 randomized, double-blind, placebo-controlled study evaluated the safety, tolerability, and pharmacokinetics (PK) after multiple-ascending doses (MAD) of orally administered SUL-238 in healthy elderly men and women (aged ≥40 years). The study included two cohorts with a treatment period of 14 days and a safety follow-up through 14 days after the last dose. 15 healthy adults in each cohort were randomized in a 2:1 ratio to receive SUL-238 or placebo. Total daily dose of SUL-238 was 4000 mg (2000 mg b.i.d., first cohort) or 4500 mg (1500 mg t.i.d., second cohort). SUL-238 demonstrated an excellent safety and tolerability profile after multiple doses in both cohorts, while demonstrating a favourable PK profile and a high cerebrospinal fluid (CSF) penetration, making it a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.Key Findings:Safety in both cohorts:No clinically significant changes were observed in physical and neurological exams, vital signs, ECG, and clinical laboratory parameters.AE rates were comparable between participants receiving SUL-238 and placebo.All AEs were of mild intensity or considered not related to SUL-238.First cohort PK (2000 mg b.i.d.):SUL-238 was rapidly absorbed with a mean time to maximum plasma concentration (Tmax) reached at 1.25(±0.54) and 1.50(±0.53) hours on day 1 and day 14, respectively.Mean terminal elimination half-life (t1/2) was3.50(±1.06) hours on day 14.Mean trough plasma concentration of SUL-238 was 39.23(±24.31) ng/mL and 41.49(±18.20) ng/mL on day 8 and day 14, respectively.Second cohort PK (1500 mg t.i.d.):SUL-238 was rapidly absorbed, with a mean time to maximum plasma concentration (Tmax) reached at 0.95(±0.16) and 1.00(±0.00) hours on day 1 and day 14, respectively.Mean terminal elimination half-life (t1/2):3.74(±1.84) hours on day 14.Mean trough plasma concentration of SUL-238 was 57.98(±31.08) and 60.63(±64.14) ng/mL on day 8 and day 14, respectively.Abidin Gülmüş, Chairman of GEN, stated:"We're greatly motivated by these new positive results of SUL-238 in our Phase 1 trial, which mark a key advance toward addressing Alzheimer's disease at its biological foundation."Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added:"With its excellent safety and PK profile in this Multiple Ascending Dose Phase 1 trial, SUL-238 continues to represent a very strong drug candidate for further clinical development aimed at meeting the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.About SUL-238SUL-238 is a novel, first-in-class, hibernation-derived small molecule designed to target mitochondria, the 'powerhouse' of the cell. SUL-238 supports mitochondrial bioenergetics via complex I/IV activation and enhances mitochondrial function in various preclinical models for neurodegenerative, cardiovascular, and renal diseases, as well as in accelerated aging. SUL-238 exhibits the capability to cross the blood-brain barrier and has undergone extensive safety evaluation in preclinical and clinical Phase 1 studies. GEN licenses SUL-238 from Sulfateq B.V. for neurodegenerative disease applications.About GEN:Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. Through significant R&D investments and global collaborations, GEN is committed to advancing healthcare worldwide. The company develops and manufactures high-quality, competitive products at its GMP-certified production facility and continues its bold efforts in original drug development via two dedicated R&D centers.About Sulfateq:Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centres to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health.For more information:www.genilac.com.trwww.sulfateqbv.comContact InformationBulutay GüneşSr. Head of Corporate Brandb.gunes@genilac.comFatih GörenInvestor Relations Managerf.goren@genilac.comSOURCE: GEN İlaç ve Sağlık Ürünleri A.Ş. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

安卡拉，土耳其, 2025年12月2日 - (亞太商訊 via SeaPRwire.com) - 土耳其領先的專業製藥公司GEN Pharmaceuticals（GENIL.IS）今日宣布，其針對首創口服型線粒體靶向藥物候選物 SUL-238 於健康老年志願者中進行的安全性、耐受性及藥代動力學（PK）評估之第一期臨床試驗取得新進展。該研究成果於今日在美國加州聖地牙哥舉行的第 18 屆阿茲海默症臨床試驗大會（CTAD）發表。SUL-238 最初由 Sulfateq 公司發現，其後透過 Sulfateq 與 GEN 的共同研發，成為治療神經退化性疾病的新型療法。這項第一期隨機、雙盲、安慰劑對照研究，評估健康老年男性與女性（年齡≥40 歲）口服 SUL-238 進行多重遞增劑量（MAD）後之安全性、耐受性及藥代動力學（PK）。研究包含兩個組別，治療期為 14 天，並於最後一次給藥後進行 14 天安全性追蹤。每組 15 名健康成人以 2:1 比例隨機分配接受 SUL-238 或安慰劑。SUL-238 每日總劑量為 4000 毫克（第一組：2000 毫克，每日兩次）或 4500 毫克（第二組：1500 毫克，每日三次）。SUL-238 在兩組受試者中均展現出優異的多劑量安全性與耐受性，同時呈現理想的藥代動力學特性及高腦脊液（CSF）滲透率，使其成為神經退化性疾病（包括阿茲海默症與帕金森氏症）後續臨床開發的潛力候選藥物。關鍵發現：兩組安全性：體格檢查、神經學檢查、生命徵象、心電圖及臨床實驗室參數均未見具臨床意義之變化。SUL-238 組與安慰劑組之不良事件發生率相當。所有不良事件強度皆屬輕度，或被判定與 SUL-238 無關。第一組別藥代動力學（2000 毫克，每日兩次）：SUL-238 吸收迅速，第 1 天與第 14 天達到血漿峰值濃度（Tmax）的平均時間分別為 1.25(±0.54)小時與 1.50(±0.53)小時。第 14 日平均終末消除半衰期(t1/2)為 3.50(±1.06)小時。SUL-238 平均谷濃度分別於第 8 日與第 14 日達 39.23(±24.31) ng/mL 及41.49(±18.20) ng/mL。第二組別藥代動力學（1500 毫克，每日三次）：SUL-238 吸收迅速，平均血漿濃度峰值達時（Tmax）分別為第 1 天 0.95(±0.16)小時與第 14 天 1.00(±0.00)小時。第 14 日平均終末消除半衰期(t1/2)：3.74(±1.84)小時。SUL-238 平均谷濃度分別於第 8 日與第 14 日達 57.98(±31.08)及 60.63(±64.14)ng/mLGEN 董事長 Abidin Gülmüş 表示：「SUL-238 在我們第一期試驗中取得的這些新正面結果，讓我們深受鼓舞，這標誌著在從生物學基礎上對抗阿茲海默症方面取得關鍵進展。」GEN 研發副總裁納迪爾·烏盧醫學博士補充道：「SUL-238 在本次多劑量遞增第一期試驗中展現卓越的安全性與藥代動力學特性，持續彰顯其作為強勢候選藥物之潛力，未來將針對神經退化性疾病（含阿茲海默症）未滿足之關鍵醫療需求推進臨床開發。」關於 SUL-238SUL-238 為首創性冬眠衍生物質小分子藥物，專注作用於細胞能量核心——線粒體。該藥物透過激活複合物 I/IV 支持線粒體生物能量代謝，並在神經退化性疾病、心血管疾病、腎臟疾病及加速衰老等多種前臨床模型中展現線粒體功能強化效果。SUL-238 具備穿越血腦屏障的能力，並已通過前臨床及臨床第一期試驗的全面安全性評估。GEN 公司從 Sulfateq B.V.取得 SUL-238 的神經退化性疾病應用授權。關於 GEN：GEN 創立於 1998 年，是土耳其領先的專業製藥公司，專注於開發跨治療領域的創新療法。透過重大研發投資與全球合作，GEN 致力推動全球醫療保健進步。該公司於符合GMP 認證的生產設施中研發製造高品質且具競爭力的產品，並透過兩座專用研發中心持續推進原創藥物開發的突破性努力。關於 Sulfateq：Sulfateq B.V. 是一家荷蘭早期生物科技公司，致力於與學術及產業研究機構建立戰略合作關係，加速創新藥物的開發進程。該公司已開發出一類新型小分子化合物——SUL 化合物，能有效維持線粒體健康狀態。更多資訊：www.genilac.com.trwww.sulfateqbv.com 聯絡資訊Bulutay Güneş企業品牌資深主管b.gunes@genilac.com Fatih Gören投資者關係經理f.goren@genilac.com SOURCE: GEN İlaç ve Sağlık Ürünleri A.Ş. Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Partnership drives clinical research, hands-on student training, and access to cutting-edge medical technologiesPETALING JAYA, Malaysia, Dec 2, 2025 - (JCN Newswire via SeaPRwire.com) - AdipoLABs Co., Ltd. and Red & Blue Co., Ltd. from Korea, together with their Malaysian subsidiary, AdipoLABs Healthcare (M) Sdn Bhd, today officially opened the new AdipoLABs regional office for Asia-Pacific, marking a strategic expansion to strengthen its leadership in non- invasive healthcare and build a robust MedTech ecosystem in Malaysia and across ASEAN.As a research and development-focused medical company, its presence is expected to drive knowledge transfer, foster R&D collaboration, provide industry-standard training, and enhance the country’s preventive healthcare capabilities. Tocommemorate this milestone, the company also signed two Memoranda of Understanding (MoUs) with the University of Cyberjaya (UoC), formalising a partnership to advance healthcare innovation, clinical research, and talent development.“By uniting our hyperthermia technology with local expertise and academic rigour, we’ll expedite the adoption of advanced solutions and improve patient outcomes worldwide. We envision this collaboration as a blueprint for international healthcare partnerships,” said Mr. Han Sung-ho, CEO of AdipoLABs Co., Ltd.A cornerstone of the first MoU is a comprehensive internship programme with UoC’s Physiotherapy programmes under the Faculty of Health, offering six-month placements and potential job opportunities to give students invaluable real-world experience. Students from the Faculty of Health will gain hands-on expertise with AdipoLABs’ Pain Bot device, enhancingtheir skills in pain detection and treatment, while students from the School of Biomedical Engineering will support AdipoLABs’ technical operations, strengthening after-sales service and device maintenance.As part of the partnership, AdipoLABs will implement a strategic client engagement initiative, where interns may be placed at client facilities to demonstrate device effectiveness and provide on-site support. This initiative highlights the interns’ value, encourages potential permanent employment, and ensures optimal use of the technology. The collaboration also extends to clinical research, with UoC professors and students conducting studies on various AdipoLABs medical devices, generating evidence-based insights to be published in reputable journals and scientifically validating the technologies.“We’re thrilled to collaborate with the University of Cyberjaya to cultivate local talent and drive Malaysian healthcareinnovation. This partnership offers UoC students invaluable hands-on experience with technologies like Pain Bot. It also expands our clinical research, enhancing pain management solutions for patients across Malaysia and ASEAN. We are dedicated to empowering future healthcare leaders,” said Dr. Isaac R. Joseph, Director of AdipoLABs Healthcare (M) Sdn Bhd.In a parallel effort to advance physiotherapy education, AdipoLABs Malaysia, Red & Blue Co., Ltd., and UoC signed a second MoU focused on knowledge transfer and medical device donation. Under this agreement, AdipoLABs Malaysia willdonate a Pain Bot unit to UoC, giving students access to cutting-edge pain detection and treatment technology and enhancing their knowledge and skills in innovative musculoskeletal pain management methods.AdipoLABs, a Ministry of Health (MOH)-registered medical-device establishment under the Medical Device Authority(MDA), anchors this collaboration with proven regulatory credibility and a strong commitment to quality and innovation. Their certified standing reinforces UoC’s ambition to accelerate evidence-based research and industry-ready healthcare solutions.“AdipoLABs’ partnership with the University of Cyberjaya is more than a collaboration, it is a direct investment in the next generation of healthcare professionals. With the introduction of advanced rehabilitative technologies, our students gain access to international-standard tools and real-world innovation that will shape their confidence, competence, and future careers,” said Professor Dr. David Whitford, Vice-Chancellor of the University of Cyberjaya.Further strengthening this collaboration, Professor Dr. Yoo Seung-mo from South Korea, the inventor of the Pain Bot, will serve as an Adjunct Professor at UoC. Dr. Yoo will provide on-site training and ongoing remote mentorship, ensuringstudents receive the highest level of expertise in utilising the Pain Bot technology and applying advanced pain detection and treatment techniques.Together, UoC and AdipoLABs are positioned to drive forward Malaysia’s healthcare innovation agenda with greater confidence and impact.For more information on University of Cyberjaya or AdipoLABs Healthcare (M) Sdn Bhd, kindly visit: University of Cyberjaya – Premier University in Malaysia or adipolabs-msia.com – AdipoLABs Healthcare MalaysiaABOUT UNIVERSITY OF CYBERJAYA (UOC)The University of Cyberjaya is a premier institution located in Malaysia's first smart city, offering a transformative educational experience on a state-of-the-art, eco-friendly campus. The University was recently ranked in the top 1,000 universities in the world under the QSWorld University Rankings and is also currently ranked top 450 under the QS Asia University Rankings 2026.The University is renowned for its excellence in medicine, teaching, employability, facilities, and social responsibility. Additionally, itholds a Top 601+ ranking in the Times Higher Education Sustainability Impact Rankings, excelling in Top 200 for Good Health and Well-being (SDG 3).Founded in 2005 with a focus on medicine and pharmacy, the University has expanded to offer over 50 programmes across diverse fields such as medicine, health sciences, nursing, pharmaceutical sciences, psychology, business, and biomedical engineering. With a globalcommunity of over 10,000 students and over 13,000 alumni, the University is shaping future leaders who are making significant contributions to various industries. The University’ impact is reflected in its graduates, who have contributed to innovations in healthcareduring the COVID-19 pandemic, participated in international humanitarian missions, and made significant advancements across industries such as business and biomedical engineering.The University is guided by Chancellor Tan Sri Dato' Seri Dr. Noor Hisham Abdullah, a prominent figure in global healthcarefor World Health Organization (WHO) initiatives and former Director-General of the Malaysian Ministry of Health. Chairman Professor Tan Sri Dato' Dr. Mohd Amin Jalaludin, former Vice-Chancellor of the University of Malaya, provides strategic governance as Chairman of the Board of Governors. Under the leadership of Vice Chancellor Professor Dr. David Whitford, the University is strengthening itsglobal outlook and academic excellence. The university can be contacted at +603 8313 7000.About AdipoLABs Co., Ltd.AdipoLABs Co., Ltd. is a South Korean medical device company specialising in innovative hyperthermia cancer treatment technology. The company is the manufacturer of the Remission 1℃, a high-frequency hyperthermia device used in hospitals worldwide as an adjunct therapy for cancer treatment. With a commitment to research and development, AdipoLABs strives to improve patient outcomes andcontribute to a future free from the burden of disease. AdipoLABs has a global presence, with branches in India, China, and Malaysia.About AdipoLABs Healthcare (M) Sdn BhdAdipoLABs Healthcare (M) Sdn Bhd, established in Malaysia in 2018, is a subsidiary of AdipoLABs Co., Ltd. As the sole distributor of AdipoLABs medical devices in Malaysia and authorised representative for sales, marketing, and after-sales service throughout the ASEAN region, the company is committed to bringing innovative, non-invasive medical devices and innovative solutions to the Southeast Asian market. The company works closely with an international team of researchers, doctors, lab technicians, and engineers toprovide cutting-edge healthcare technology to the ASEAN market. Dr. Isaac R. Joseph and Mr. Moses Balagopal are the Directors and Co-founders of AdipoLABs Healthcare (M) Sdn Bhd.About Red & Blue Co., Ltd.Red & Blue Co., Ltd. is a South Korean company specialising in the development and distribution of advanced medical devices andhealthcare solutions. As a key partner of AdipoLABs Co., Ltd., Red & Blue Co., Ltd. is committed to supporting education and traininginitiatives that promote the effective use of innovative pain detection and pain treatment techniques. Dr. Yoo works closely with healthcare professionals and academic institutions to advance the field of pain management and improve patient outcomes.Issued by MNAIR PR Consultancy Sdn Bhd on behalf of University of Cyberjaya and AdipoLABs Healthcare (M) Sdn Bhd Contacts for Media Enquiries:MNAIR PR Consultancy Sdn Bhd Ameera HaniAssociate Director, Public Relations+6014 2243296ameera@mnairpr.comUniversity of Cyberjaya (UoC) Ehya NadzeriCommunicationsCyberjaya Education Group Berhad gcmc@cyberjaya.edu.my Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月2日 - (亞太商訊 via SeaPRwire.com) - 試驗數據再次驗證，HTD1801靶向2型糖尿病發生及發展的根源性問題，實現更全面的心血管代謝綜合獲益。君聖泰醫藥（股票代碼：2511.HK），一家專注于開發多功能創新療法，以解決代謝性慢病未滿足臨床需求的創新藥公司，宣佈HTD1801在2型糖尿病（T2DM）患者中開展的與達格列淨頭對頭的臨床III期試驗（HARMONY）取得了積極的結果，試驗達到主要終點，並在多項關鍵心血管代謝指標的改善上優於達格列淨。HARMONY（NCT06415773）是一項隨機、雙盲、陽性藥物對照的III期臨床研究（N=369），旨在評估HTD1801與達格列淨相比，在二甲雙胍治療後血糖控制不佳的成年T2DM患者中的有效性與安全性。研究的主要終點為：治療24周後HbA1c相對於基線的變化（非劣效界值為0.4%）。次要終點包括多項心血管代謝指標。- 達成主要終點：HTD1801治療24周後，HbA1c的最小二乘（LS）均值變化為-1.12%，達格列淨組為-0.93%（LS均值差異：-0.20%；95% CI：-0.37 ~ -0.03；P < 0.001）。- 達成多項次要終點：相較達格列淨，HTD1801在LDL-C與non-HDL-C降低方面明顯更優，需要新增或強化他汀類治療的患者比例也顯著低於達格列淨組。HTD1801還在多個心血管代謝指標的改善上優於達格列淨，如治療後有更高比例的患者達到HbA1c<7.0%的控制目標，以及更大的Lp(a)降幅。- HTD1801具有良好的安全性與耐受性，嚴重不良事件的發生率為3.8%（達格列淨組為4.4%）。HTD1801組最常見的不良事件為輕至中度胃腸道不良反應，且未見嚴重低血糖事件。綜合而言，相較於SGLT2抑制劑，HTD1801通過同時調控代謝與炎症通路，更精准地靶向T2DM的核心病理機制，可為T2DM患者帶來更為全面的臨床獲益。繼 SYMPHONY-1和SYMPHONY-2試驗之後，HARMONY是HTD1801第三項取得積極結果的III期試驗，進一步驗證了其成為心腎代謝疾病（CKM）基礎治療藥物的強大潛力。君聖泰醫藥計畫於今年內啟動HTD1801項目的新藥上市申請（NDA）。該臨床試驗的主要研究者，前國際糖尿病聯盟（IDF）副主席、北京大學糖尿病中心主任、北京大學人民醫院內分泌和代謝科主任紀立農教授指出："HARMONY研究數據顯示HTD1801降糖效果優於降糖藥物SGLT2抑制劑達格列淨，同時比具有已經被證明有顯著心腎保護作用的達格列淨有更強的降低導致動脈粥樣硬化性心血管的低密度脂蛋白的作用，並減少他汀類藥物的治療需求。這提示HTD1801 可能具有更強的改善動脈粥樣硬化性心血管疾病的潛力。我們非常期待該藥物上市，使這項創新療法惠及患者。"君聖泰醫藥的創始人、董事長兼首席執行官劉利平博士表示："HARMONY研究數據讀出是HTD1801全球開發進程中的又一項關鍵里程碑。隨著三項III期臨床試驗的相繼成功完成，作為全球首創且兼具"一藥多效"特性的創新藥物，HTD1801持續展現其治療潛力，有望補充甚至突破SGLT2抑制劑的治療邊界，為T2DM患者提供更全面的治療方案。"關於HTD1801HTD1801是一款全球首創的新分子實體，旨在解決心腎代謝系統疾病（CKM）的未滿足臨床需求。HTD1801作為單一分子，是具有獨特雙機制的口服抗炎及代謝調節劑（AIMM），通過啟動AMPK及抑制NLRP3炎症小體發揮其生物學活性；這種互補協同的雙機制作用可有效解決代謝問題。全球多項臨床結果驗證HTD1801具有"一藥多效"的特性，能夠為患者帶來綜合獲益，包括改善胰島素敏感性、血糖控制、血脂降低、腎臟保護、體重減輕、肝臟獲益及抗炎等。基於此，HTD1801有潛力成為CKM領域的基礎性治療藥物。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月2日 - (亞太商訊 via SeaPRwire.com) - 近日，香港中國金融協會2025年度論壇「香港數字金融中心建設的機遇與挑戰」暨「跨境金融及金融創新服務大獎」颁獎典禮於香港會議展覽中心隆重舉行。本次活动由香港中國金融協會主辦，天風國際證券集團有限公司（以下簡稱「天風國際」）作為特別支持單位全程服務活動籌辦，香港中國金融協會永遠名譽主席胡章宏，香港大學經管學院教授、香港中國金融協會顧問、中誠信國際首席經濟學家毛振華，泰康保險集團執行副總裁兼首席投資官、泰康資產總經理兼首席執行官段國聖，HashKey集團新加坡总裁兼HashKey Capital首席執行官鄧超等出席活动並担任論壇重要演講嘉宾，圍繞「香港金融角色再定位」、「變局環境下資產管理行業的挑戰與應對」、「加密資產行業現狀與趨勢」等主題，共議香港金融同業如何「破局金融未來」。論壇吸引了香港政商界領袖、上市公司負責人、知名經濟學家、相關行業專家等近300位嘉賓出席。主禮嘉賓及香港中國金融協會代表合影留念以聯通為錨，共探數字金融中心建設盡管當前全球政經格局複雜多變，香港仍保持著領先的國際金融中心地位。2025年，香港在金融科技領域排名躍升至全球首位，在多個金融行業領域從業員的評價中，香港亦名列前茅，其中在「銀行業」、「投資管理」、「保險業」及「融資」均繼續保持全球三甲內。伴隨國際經濟多元化趨勢加强，香港作爲中外資產的「超級聯繫人」和「超級增值人」角色愈加凸顯。香港中國金融協會主席孟羽在視頻致辭中指出，香港背靠祖國、聯通世界，「一國兩制」的獨特優勢為香港築牢了行穩致遠的發展根基，金融業的創新發展亦將為香港經濟社會的持續繁榮增添動力。「本次活動緊扣跨境金融與科技創新深度融合的時代命題，在匯聚行業專家探討金融数字化趋势、真实世界资产代币化落地等發展方向之外，期望發掘更多引領行業發展的創新實踐,著力推動香港金融行業在變局中化挑戰為機遇」,孟羽補充。香港中國金融協會主席孟羽視頻致辭胡章宏在致辭中強調，當前，國家正堅定不移地推進金融強國建設，並提出了要做好科技、綠色、普惠、養老、數字等關於金融的五篇大文章的戰略部署。「國家的戰略藍圖，為香港金融業的發展提供了前所未有機遇，也賦予了香港特殊的歷史使命--那就是成為國家金融戰略的『超級聯繫人』，將國家宏觀戰略與全球金融市場精準對接，在服務國家大局中實現自身更大的發展。」香港中國金融協會永遠名譽主席胡章宏作開幕致辭毛振華表示，當前香港依然是中國與國際進行資本往來的重要橋樑。「在外國直接投資方面，我們有60%的資金通過香港進入內地;在境外直接投資方面，也有60%以上的資金首先抵達香港。整體上，香港仍然是中國資本出海的首選。」他說。他進一步指出，香港正從傳統、單一資本通道，擴展為提供全鏈條金融與專業服務的綜合平台。面對中國企業從「産能出海」邁向「技術與模式出海」的新浪潮，香港憑藉與國際完全接軌的法律、金融及專業服務體系，正成為護航中國資本全球化配置、對接國際標準運營的關鍵支點。中誠信集團董事長、香港大學經管學院教授、香港特首政策專家組成員毛振華作主旨演講在資產管理方面，段國聖認為，當前行業主要面臨人工智能技術革新與國際環境變化的雙重挑戰。他觀察到，國際資管巨頭已將AI深度應用於投資研究、策略構建及風險管理，所以中港機構在此領域應積極佈局大數據、人工智能在信息收集、研究、投資決策、投資策略及風險控制等諸多領域的工作，並構建系統化的投資。此外，他還倡導行業應堅守中性策略，避免極端路徑，並指出構建絕對收益能力，方能在變局中立於不敗之地。泰康保險集團執行副總裁兼首席投資官、泰康資產總經理兼首席執行官段國聖作主旨演講與此同時，香港更是推動數字金融及數字資產發展的先行者。鄧超指出：「香港早於2018年已推出虛擬資產監管框架，時至今日，其在監管、牌照與產品等方面均處於亞洲領先地位。」他進一步表示，當前數字資產行業已超越早期的技術探索，正邁向以金融應用為主導的「專業化」與「機構化」新階段。他認為，鏈上資產資本化與線下資產鏈上化的雙向奔赴,將成為行業發展最具有革命性的趨勢。在此趨勢下，加密貨幣及代幣化將成為未來金融行業監管的重要任務。 HashKey集團新加坡總裁兼HashKey Capital首席執行官鄧超作主旨演講以科技為軸，携手開拓金融破局之道本次年度主題論壇特設圓桌討論，該環節由香港中國金融協會副主席、香港金融科技公司Volmart首席執行官楊再勇主持，並邀請到招銀國際資產管理部主管、董事總經理白海峰，中國太保投資管理有限公司行政總裁及執行董事周成崗，浩宸律師事務所合夥人李再浩, SNZ Holding首席投資官王克一一同，圍繞「香港RWA的實例與挑戰」話題，就RWA(現實世界資產)核心價值、香港優勢、行業現狀與挑戰等方面深入交流,共同展望未來香港RWA的發展方向。（從左至右）香港中國金融協會副主席、Volmart首席執行官楊再勇，招銀國際資產管理部主管、董事總經理白海峰，中國太保投資管理有限公司行政總裁及執行董事周成崗，浩宸律師事務所合夥人李再浩, SNZ Holding首席投資官王克一。白海峰指出，RWA在鏈上的交易效率遠超傳統支付網路，展現了可編程金融的巨大潛力。他預期，在2025年香港穩定幣監管條例落地後，合規穩定幣將釋放更大能量。周成崗與李再浩則強調了RWA在解決流動性、降低投資門檻及實現全球資產准入方面的潛力。周成崗稱，RWA通過代幣化，可以將原本僅面向特定投資者的資產開放給更廣泛的零售市場，甚至實現全球範圍的資產准入，進而形成新金融範式。李再浩則以自身為例，指出代幣化將能讓他國投資者更方便地在香港進行投資。從Web3視角出發，王克一表示，RWA的價值基礎在於區塊鏈提供的信任與安全，同時RWA在效率以及隱私等方面也有獨特價值貢獻。談及行業現狀，白海峰認為，RWA的價值仍然要取決於資產上鏈後能否解決實際痛點，不能為上鏈而上鏈。周成岗呼籲RWA行業自律,且需通過進一步制定行業準則、代表行業與監管溝通，以推動健康發展。嘉賓們對香港RWA短期内的發展均持審慎樂觀態度，認為需要時間讓市場和監管逐步成熟，但中長期來看，仍對香港成為全球RWA中心充滿信心。以創新為翼，齊聚英才見證發展成果年度論壇之后，2025年度「跨境金融及金融創新服務大獎」颁獎典禮隆重舉行。本届大獎以「破局金融未來」為主題，聚焦跨境金融、科技金融與綠色金融等前沿領域，並突破性地採用通證化投票方式，旨在為香港金融業界提供一個優質的業務成果展示平台,在促進行業交流、促成業務合作之餘，號召業界人士攜手推動香港金融業轉型升級。大獎設置卓越方案獎、優秀方案獎兩大類別。經過嚴格評審，獲得卓越方案獎的團隊共3個(排名不分先後)，分別來自光銀國際資本有限公司、工銀資管(全球)有限公司、交通銀行(香港)有限公司。香港中國金融協會副主席、野村證券中國首席經濟學家陸挺，香港中國金融協會副主席、國泰海通獨立非執行董事、交銀國際非執行董事、弘源資本高級顧問浦永灝為獲獎團隊頒發獎項。香港中國金融協會副主席、野村證券中國首席經濟學家陸挺（右一），香港中國金融協會副主席、海通國際獨立非執行董事、交銀國際非執行董事、弘源資本高級顧問浦永灝（左一）與獲獎團隊合影留念獲得優秀方案獎的團隊共11個(以下排名不分先後) 。香港中國金融協會副主席、時和資產管理有限公司董事長兼總裁陳東，香港中國金融協會副主席、美銀美林亞太區董事總經理劉瑾為獲獎團隊頒獎，他們分別是：創興銀行有限公司、招商永隆銀行有限公司、中國建設銀行(亞洲)股份有限公司、中國工商銀行（亞洲）有限公司、泰康資產管理（香港）有限公司。香港中國金融協會副主席、時和資產管理有限公司董事長兼總裁陳東（左一）,香港中國金融協會副主席、美銀美林亞太區董事總經理劉瑾（右一）與獲獎團隊合影留念泰康保險集團執行副總裁兼首席投資官、泰康資產總經理兼首席執行官段國聖，香港中國金融協會副主席、天風國際行政總裁鄒傳為獲獎團隊頒獎，他們分別是：國聯證券（香港）有限公司、中國銀河國際控股有限公司、亞丁金融集團有限公司、招銀國際資產管理有限公司、CHAMP ACE District、聯合評級國際有限公司。泰康保險集團執行副總裁兼首席投資官、泰康資產總經理兼首席執行官段國聖（左一），香港中國金融協會副主席、天風國際行政總裁鄒傳（右一）與獲獎團隊合影留念展望未來，香港中國金融協會將積極響應國家金融强國戰略，把握好香港作爲國際金融中心的區域優勢，面向世界、聯通內外，以金融創新引領行業升級，以數字科技破局金融未來,持續為香港金融行業的可持續發展注入新動能。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com